Drugs in the Pipeline

PolyMedix has successfully completed its first-in-man Phase 1 clinical study with the novel heparin antagonist drug PMX-60056.

Avineuro Pharmaceuticals announced an initiation of Phase I clinical studies of AVN-211, a potent and selective small molecule antagonist of 5-HT6 receptor for treatment of schizophrenia.

AVEO Pharmaceuticals announced the initiation of a Phase 1b/2a clinical trial of AV-951 as monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC).

Advaxis submitted ADXS11-001 (formerly known as Lovaxin-C) to the FDA for orphan drug designation to treat invasive carcinoma of the cervix.

Celator Pharmaceuticals announced that the first patient has been treated in its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus intensive salvage therapy in adult patients (up to 60 years old) with acute myeloid leukemia (AML) in first relapse.